Belfast Health and Social Care Trust
caring supporting improving together

FOI/38454

20 October 2026

Incidence and Treatment of Breast Cancer Jul-Sep 2026

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

- Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) **0**
- Abemaciclib + Fulvestrant **6**
- Alpelisib + Fulvestrant **0**
- Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide only **<5**
- Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Paclitaxel **6**
- Atezolizumab **0**
- Capivasertib **0**
- Capecitabine as a single agent **44**
- Carboplatin + Paclitaxel **0**
- Elacestrant **0**
- Eribulin as a single agent or in combination **10**
- Everolimus + Exemestane **0**
- Fulvestrant as a single agent **27**
- Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) **0**
- Palbociclib + Fulvestrant **5**
- Parp Inhibitors (Olaparib/Talazoparib) **5**
- Pembrolizumab Monotherapy **<5**
- Pembrolizumab + Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide **<5**
- Carboplatin + Paclitaxel + Pembrolizumab **0**
- Pertuzumab (Perjeta) + Trastuzumab (Herceptin) **0**
- Phesgo (Pertuzumab + Trastuzumab in a single injection) **0**
- Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole**)** **0**
- Ribociclib + Fulvestrant **<5**
- Sacituzumab Govitecan **<5**
- Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent **21**
- Trastuzumab deruxtecan (Enhertu) **17**
- Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel **30**
- Trastuzumab emtansine (Kadcyla) **9**

Any other active systemic anti-cancer therapy

Abemaciclib SA **64**, Atezolizumab + NabPaclitaxel **<5**, Capivasertib + Fulvestrant **5**, docetaxel+Cyclophosphamide **<5**, D-Phesgo **7**, EC-D+Trast <5, EC-D 22, ECDPhesgo **16**, EC-Pac/Carbo **22**, EPCPPhesgo **10**, FEC WklyP HER **<5**, Goserelin **6**, Neratinib **<5**, Palbociclib SA **39**, Ribociclib **62**, Tucat Cab Tras **6**, Vinorelbine <**5**, Weekly Pac Phesgo 10, Zoledronic Acid **8**

20 October 2026

Q2. Does your trust participate in any clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part.

Project Short title	Project Full title - Breast cancer studies open to recruitment at Belfast HSC Trust	Belfast recruited at 01.10.26
ATNEC	ATNEC–Axillary management in T1-3N1M0 breast cancer patients with FNA or core biopsy proven nodal metastases at presentation who convert to node negative after NEoadjuvant Chemotherapy	8
EndoNET	Randomised controlled trial evaluating effectiveness of neoadjuvant endocrine treatment in post-menopausal women	<5
FAST-Forward Boost	A randomised clinical trial testing a 1-week schedule of curative simultaneous integrated boost radiotherapy against a standard 3-week schedule in patients with early breast cancer	38
HER2-RADiCAL	The HER2-RADiCAL study (Response ADaptive CAre pLan) – Tailoring treatment for HER2 positive early breast cancer	5
LOLIPOP	Long-term Outcomes of Lidocaine Infusions for persistent Post-Operative Pain in patients undergoing breast surgery (LOLIPOP) Trial	18
PHOENIX Trial	PHOENIX Trial: A pre-surgical window of opportunity and post-surgical adjuvant biomarker study of DNA damage response inhibition and/or anti-PD-L1 immunotherapy in patients with neoadjuvant chemotherapy resistant residual triple negative breast cancer	<5
REPOWER	REPOWER: "Real-world Evaluation of Patient Outcomes and Experiences with Ribociclib Early Adopters: A Hybrid Study with Prospective Patient-reported Outcomes and Retrospective Clinical Chart Review"	6
TADPOLE v1.0	Targeted Axillary Dissection versus axillary node clearance in patients with Positive axillary Lymph nodes in Early breast cancer: A multicentre, pragmatic, phase III randomised controlled trial	0

Where numbers are low, we have indicated <5 rather than provide the exact figure. Releasing such small numbers has the potential to make people identifiable and disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018. This information is therefore exempt from release under Section 40(2) of the Freedom of Information Act 2000 – Information Relating to a Third Party.